vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.
OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $9.4M, roughly 1.4× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs -488.0%, a 2421.9% gap on every dollar of revenue. On growth, Broadway Financial Corp posted the faster year-over-year revenue change (10.1% vs -22.4%). Broadway Financial Corp produced more free cash flow last quarter ($-13.0K vs $-57.1M). Over the past eight quarters, Broadway Financial Corp's revenue compounded faster (9.7% CAGR vs -5.3%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.
BYFC vs OCUL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $9.4M | $13.3M |
| Net Profit | $1.0M | $-64.7M |
| Gross Margin | — | 88.0% |
| Operating Margin | — | -526.5% |
| Net Margin | 1934.0% | -488.0% |
| Revenue YoY | 10.1% | -22.4% |
| Net Profit YoY | -21.8% | -33.6% |
| EPS (diluted) | $0.02 | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $13.3M | ||
| Q3 25 | $9.0M | $14.5M | ||
| Q2 25 | $8.1M | $13.5M | ||
| Q1 25 | $8.3M | $10.7M | ||
| Q4 24 | $8.6M | $17.1M | ||
| Q3 24 | $8.7M | $15.4M | ||
| Q2 24 | $8.2M | $16.4M | ||
| Q1 24 | $7.8M | $14.8M |
| Q4 25 | $1.0M | $-64.7M | ||
| Q3 25 | $-23.9M | $-69.4M | ||
| Q2 25 | $752.0K | $-67.8M | ||
| Q1 25 | $-2.7M | $-64.1M | ||
| Q4 24 | $1.3M | $-48.4M | ||
| Q3 24 | $516.0K | $-36.5M | ||
| Q2 24 | $256.0K | $-43.8M | ||
| Q1 24 | $-154.0K | $-64.8M |
| Q4 25 | — | 88.0% | ||
| Q3 25 | — | 87.8% | ||
| Q2 25 | — | 85.6% | ||
| Q1 25 | — | 88.2% | ||
| Q4 24 | — | 92.8% | ||
| Q3 24 | — | 89.9% | ||
| Q2 24 | — | 90.8% | ||
| Q1 24 | — | 91.0% |
| Q4 25 | — | -526.5% | ||
| Q3 25 | -256.2% | -472.3% | ||
| Q2 25 | 12.8% | -502.6% | ||
| Q1 25 | -45.3% | -597.5% | ||
| Q4 24 | 21.7% | -296.1% | ||
| Q3 24 | 8.5% | -298.2% | ||
| Q2 24 | 4.8% | -265.1% | ||
| Q1 24 | -2.9% | -214.0% |
| Q4 25 | 1934.0% | -488.0% | ||
| Q3 25 | -264.2% | -477.3% | ||
| Q2 25 | 9.3% | -503.9% | ||
| Q1 25 | -32.3% | -598.7% | ||
| Q4 24 | 15.3% | -283.3% | ||
| Q3 24 | 5.9% | -236.6% | ||
| Q2 24 | 3.1% | -266.3% | ||
| Q1 24 | -2.0% | -438.9% |
| Q4 25 | $0.02 | $-0.27 | ||
| Q3 25 | $-2.86 | $-0.38 | ||
| Q2 25 | $0.00 | $-0.39 | ||
| Q1 25 | $-0.39 | $-0.38 | ||
| Q4 24 | $0.07 | $-0.25 | ||
| Q3 24 | $-0.03 | $-0.22 | ||
| Q2 24 | $0.02 | $-0.26 | ||
| Q1 24 | $-0.02 | $-0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $737.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $654.3M |
| Total Assets | $1.3B | $808.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $737.1M | ||
| Q3 25 | $19.7M | $344.8M | ||
| Q2 25 | $29.5M | $391.1M | ||
| Q1 25 | $15.8M | $349.7M | ||
| Q4 24 | $61.4M | $392.1M | ||
| Q3 24 | $97.1M | $427.2M | ||
| Q2 24 | $89.8M | $459.7M | ||
| Q1 24 | $67.1M | $482.9M |
| Q4 25 | $262.8M | $654.3M | ||
| Q3 25 | $261.7M | $258.2M | ||
| Q2 25 | $284.7M | $305.9M | ||
| Q1 25 | $283.6M | $265.9M | ||
| Q4 24 | $285.0M | $315.3M | ||
| Q3 24 | $286.2M | $352.0M | ||
| Q2 24 | $282.1M | $377.7M | ||
| Q1 24 | $281.1M | $408.0M |
| Q4 25 | $1.3B | $808.1M | ||
| Q3 25 | $1.3B | $410.9M | ||
| Q2 25 | $1.2B | $451.3M | ||
| Q1 25 | $1.3B | $405.9M | ||
| Q4 24 | $1.3B | $457.9M | ||
| Q3 24 | $1.4B | $490.4M | ||
| Q2 24 | $1.4B | $517.1M | ||
| Q1 24 | $1.4B | $538.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-54.2M |
| Free Cash FlowOCF − Capex | $-13.0K | $-57.1M |
| FCF MarginFCF / Revenue | -0.1% | -430.9% |
| Capex IntensityCapex / Revenue | 2.6% | 21.4% |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | $-216.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-54.2M | ||
| Q3 25 | $3.8M | $-50.7M | ||
| Q2 25 | $3.0M | $-55.2M | ||
| Q1 25 | $-4.3M | $-44.7M | ||
| Q4 24 | $1.4M | $-39.4M | ||
| Q3 24 | $6.1M | $-36.6M | ||
| Q2 24 | $9.8M | $-24.8M | ||
| Q1 24 | $-11.7M | $-33.9M |
| Q4 25 | $-13.0K | $-57.1M | ||
| Q3 25 | $3.7M | $-56.7M | ||
| Q2 25 | $3.0M | $-56.5M | ||
| Q1 25 | $-4.4M | $-46.6M | ||
| Q4 24 | $1.3M | $-39.6M | ||
| Q3 24 | $6.1M | $-36.6M | ||
| Q2 24 | $9.7M | $-25.5M | ||
| Q1 24 | $-11.7M | $-34.1M |
| Q4 25 | -0.1% | -430.9% | ||
| Q3 25 | 41.1% | -390.0% | ||
| Q2 25 | 37.0% | -419.7% | ||
| Q1 25 | -52.4% | -435.6% | ||
| Q4 24 | 14.7% | -232.0% | ||
| Q3 24 | 69.6% | -237.6% | ||
| Q2 24 | 118.9% | -155.4% | ||
| Q1 24 | -149.7% | -231.1% |
| Q4 25 | 2.6% | 21.4% | ||
| Q3 25 | 1.2% | 41.2% | ||
| Q2 25 | 0.2% | 9.3% | ||
| Q1 25 | 0.2% | 18.1% | ||
| Q4 24 | 1.6% | 1.2% | ||
| Q3 24 | 0.3% | 0.6% | ||
| Q2 24 | 0.5% | 4.5% | ||
| Q1 24 | 0.7% | 1.7% |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.